Inclusion Criteria:

Patients are included in the study if all of the following criteria are met: Patients
confirmed to have multiple myeloma (symptomatic myeloma) defined in the diagnostic
criteria of the International Myeloma Working Group (IMWG).

- Patients with measurable lesions

- Patients with no history of treatment (no history of chemotherapy or radiotherapy)

- Patients should not be considered candidates for high dose therapy/autologous stem
cell transplantation due to coexistent medical conditions, advanced age, poor
performance status, refusal of high dose chemotherapy, or other reasons as judged by
the patient and/or physician.

- Expected survival of at least 3 months

- Patients aged between 20 and 79 years (at the time of provisional registration)

- Performance status (P.S.) grade 0-2. P.S. 3 possible only for osteolytic lesions

- Patients with adequately maintained organ function (e.g., bone marrow, heart, lungs,
liver, kidneys,)

- Patients from whom written consent to participate in this study has been obtained.

Exclusion Criteria:

Patients are excluded from participating in the study if 1 or more of the following
criteria are met:

- Patients with apparent infections (including viral infections)

- Patients with serious complications (hepatic failure, renal failure, or diabetes with
insulin administration)

- Patients with complications or a medical history of serious cardiac disease (e.g.,
myocardial infarction, ischemic heart disease) within 2 years before preliminary
registration. Patients with arrhythmia requiring treatment.

- Patients with serious gastrointestinal symptoms (profound or serious nausea /
vomiting or diarrhea, etc.)

- Patients who were hepatitis B virus antigen (HBsAG)-positive, hepatitis C virus (HCV)
antibody-positive or human immunodeficiency virus (HIV) antibody-positive

- Patients with a serious bleeding tendency [e.g., Disseminated intravascular
coagulation (DIC)]

- Patients with interstitial pneumonia, pulmonary fibrosis or pulmonary emphysema
requiring treatment, or such diseases in the past

- Patients with apparent amyloidosis as a complication

- Patients with clinical symptoms of invasion or suspected invasion of the central
nervous system.

- Patients with active multiple cancers

- Patients who have or previously had autoimmune hemolytic anemia.

- Patients administered this investigational drug in the past

- Patients who received hematopoietic stem cell transplantation in the past.

- Patients who received cytokines such as granulocyte colony stimulating factor (G-CSF)
or erythropoietin or a blood transfusion within 1 week before the screening
examination prior to preliminary registration for this study

- Patients who were administered an investigational drug during a clinical study or an
unapproved drug within 3 months prior to preliminary registration in this study

- Patients with prior allergies to medications similar to the investigational drug
(e.g., alkylating agents, or purine nucleotide analogs), mannitol or prednisolone

- Patients with drug addiction, narcotic addiction or alcoholism.

- Patients who were pregnant, breastfeeding women or who had a possibility to be
pregnant

- Patients who do not agree to contraception during the following periods. For males,
during or for 6 months after completion of administration of the investigational
drug. For females, during or for 3 months after completion of administration of the
investigational drug

- Patients whom the investigator or the sub-investigators considered to be
inappropriate for the study